| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/26/2007 | CA2600914A1 Inhibitors of checkpoint kinases |
| 07/25/2007 | EP1811038A1 Processes for producing cellooligosaccharide |
| 07/25/2007 | EP1811035A1 Aspartic proteinase 2 (ASP2) |
| 07/25/2007 | EP1811033A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 07/25/2007 | EP1811025A1 Mutated amyloid protein |
| 07/25/2007 | EP1811024A1 Oligo double-stranded rna and medicinal composition |
| 07/25/2007 | EP1811018A1 Brain disposition marrow progenitor |
| 07/25/2007 | EP1810976A1 Benzonaphthaceneglycoside derivative and use thereof |
| 07/25/2007 | EP1810973A1 6-monoacetylmorphine derivatives useful in immunoassay |
| 07/25/2007 | EP1810971A1 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| 07/25/2007 | EP1810970A1 Therapeutic piperazine compounds |
| 07/25/2007 | EP1810969A1 Aryloxy-substituted benzimidazole derivatives |
| 07/25/2007 | EP1810968A2 9, 10-a, a-OH-texane analogs and methods for production thereof |
| 07/25/2007 | EP1810965A1 Hydrazide derivatives |
| 07/25/2007 | EP1810715A2 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity |
| 07/25/2007 | EP1810714A1 Use of a combination of heroin and naloxon for drug substitution |
| 07/25/2007 | EP1810695A1 Non-aqueous liquid shampoo composition |
| 07/25/2007 | EP1810694A2 Water-soluble compositions of bioactive lipophilic compounds |
| 07/25/2007 | EP1810693A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 07/25/2007 | EP1810691A2 Immunotherapy for reversing immune suppression |
| 07/25/2007 | EP1810689A1 Preventive and/or therapeutic agent for diabetes |
| 07/25/2007 | EP1810684A2 Anticancer agent |
| 07/25/2007 | EP1810681A1 Intestinal polyp inhibitor |
| 07/25/2007 | EP1810680A2 Compositions and methods for use in targeting vascular destruction |
| 07/25/2007 | EP1810679A2 Controlled release oxycodone compositions |
| 07/25/2007 | EP1810678A1 Use of morphine and naloxone for drug substitution |
| 07/25/2007 | EP1810677A1 Receptor function regulating agent |
| 07/25/2007 | EP1810676A1 Levetiracetam formulations and methods for their manufacture |
| 07/25/2007 | EP1810675A1 Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| 07/25/2007 | EP1810674A1 Stable pharmaceutical composition containing carisoprodol and meloxicam |
| 07/25/2007 | EP1810673A1 Therapeutic agent for interstitial cystitis |
| 07/25/2007 | EP1810672A1 Veterinary use of a pleuromutilin derivative against secondary pneumonia in swine |
| 07/25/2007 | EP1810671A1 Agent for recovery from cerebral fatigue |
| 07/25/2007 | EP1810670A1 Combination of Polamidone and Naloxone for the treatment of drug addiction |
| 07/25/2007 | EP1810669A1 Application form for burprenorphine |
| 07/25/2007 | EP1810668A1 Coated formulations containing tolterodine tartrate |
| 07/25/2007 | EP1810667A1 Pharmaceutical composition comprising amorphous atorvastatin |
| 07/25/2007 | EP1810666A1 Foam-Forming composition |
| 07/25/2007 | EP1810665A1 Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
| 07/25/2007 | EP1809742A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 07/25/2007 | EP1809734A2 Disease treatment via developing non-syngeneic graft transplantation |
| 07/25/2007 | EP1809687A1 Biocide in particular an agent with fungicidal activity |
| 07/25/2007 | EP1809678A2 Photocrosslinkable poly(caprolactone fumarate) |
| 07/25/2007 | EP1809674A1 Process for producing natural immunobiotic extract and uses thereof |
| 07/25/2007 | EP1809650A2 Polymorphs of sarsapogenin |
| 07/25/2007 | EP1809648A2 Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents |
| 07/25/2007 | EP1809645A1 Antimicrobial 2-deoxystreptamine compounds |
| 07/25/2007 | EP1809639A2 8a, 9-dihydro-4a-h-isothiazolo[5,4-b] quinoline-3, 4-diones and related compounds as anti-infective agents |
| 07/25/2007 | EP1809636A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| 07/25/2007 | EP1809633A1 Constrained compounds as cgrp-receptor antagonists |
| 07/25/2007 | EP1809632A2 Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors |
| 07/25/2007 | EP1809631A1 Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| 07/25/2007 | EP1809630A1 4-amino-5-oxo-8-phenyl-5h-pyrido-[2,3-d]-pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours |
| 07/25/2007 | EP1809629A1 N,n'-diphenyl urea derivatives suitable as kinase inhibitors |
| 07/25/2007 | EP1809628A1 Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors |
| 07/25/2007 | EP1809626A2 Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
| 07/25/2007 | EP1809624A1 Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| 07/25/2007 | EP1809623A1 Process for the preparation of irbesartan hydrochloride |
| 07/25/2007 | EP1809622A1 Inhibitors of the interaction between mdm2 and p53 |
| 07/25/2007 | EP1809621A1 Methods of preparing indazole compounds |
| 07/25/2007 | EP1809620A1 Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 07/25/2007 | EP1809619A1 Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
| 07/25/2007 | EP1809618A1 Chroman derivatives, medicaments and use in therapy |
| 07/25/2007 | EP1809614A2 Benzotriazine inhibitors of kinases |
| 07/25/2007 | EP1809613A2 Methods of making 2,6-diaryl piperidine derivatives |
| 07/25/2007 | EP1809612A1 Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
| 07/25/2007 | EP1809611A1 Reversed pyrimidinone compounds as calcilytics |
| 07/25/2007 | EP1809608A1 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| 07/25/2007 | EP1809607A1 Sulfonyl benzimidazole derivatives |
| 07/25/2007 | EP1809606A1 Compounds having activity at nk3 receptor and uses thereof in medicine |
| 07/25/2007 | EP1809605A1 Quinoline as allosteric enhancers of the gaba-b receptors |
| 07/25/2007 | EP1809603A1 Nitrobenzindoles and their use in cancer therapy |
| 07/25/2007 | EP1809602A1 Indole derivatives useful as progesterone receptor modulators |
| 07/25/2007 | EP1809601A2 Compounds for alzheimer's disease |
| 07/25/2007 | EP1809600A2 Cyclic b-amino acid derivatives as factor xa inhibitors |
| 07/25/2007 | EP1809598A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/25/2007 | EP1809597A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/25/2007 | EP1809594A1 Estrogen receptor modulators |
| 07/25/2007 | EP1809381A2 Use of compounds for the prevention of drug-induced cell toxicity |
| 07/25/2007 | EP1809379A2 Process for preparing (3-(2(r)-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3(s)-(4-fluorophenyl)morpholin-4-yl)methyl)-5-oxo-4,5-dihydro-(1,2,4)-triazol-1-yl) phosphonic acid |
| 07/25/2007 | EP1809330A2 Methods and compositions for reducing toxicity of a pharmaceutical compound |
| 07/25/2007 | EP1809329A2 Sustained local anesthetic composition containing prefrably a sugar ester such as saib |
| 07/25/2007 | EP1809328A1 Compositions having body fat reducing function and food and drink containing the same |
| 07/25/2007 | EP1809312A1 Use of 11-oh-erythravine, erythravine, erytrartine, pharmaceutical compositions and processes for producing these substances |
| 07/25/2007 | EP1809307A1 Medical solution, method for producing and use thereof |
| 07/25/2007 | EP1809304A2 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
| 07/25/2007 | EP1809302A1 Antisens modulation of integrin alpha-4 expression |
| 07/25/2007 | EP1809300A1 Method for treating bacterial infections in horses or pigs with tilmicosin |
| 07/25/2007 | EP1809299A2 Phosphonate substituted kinase inhibitors |
| 07/25/2007 | EP1809298A2 Neuroprotective spirostenol pharmaceutical compositions |
| 07/25/2007 | EP1809297A1 Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders |
| 07/25/2007 | EP1809296A2 Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists |
| 07/25/2007 | EP1809295A2 Novel formulations of eprosartan with enhanced bioavailability |
| 07/25/2007 | EP1809294A2 Compounds for inflammation and immune-related uses |
| 07/25/2007 | EP1809293A2 Aerosol formulation for inhalation of beta agonists |
| 07/25/2007 | EP1809292A2 Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes |
| 07/25/2007 | EP1809291A1 Pharmaceutical compositions for transdermal delivery |
| 07/25/2007 | EP1809290A2 Pyrimidine derivatives as ion channel modulators and methods of use |
| 07/25/2007 | EP1809289A1 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| 07/25/2007 | EP1809288A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |